Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?

被引：8

作者：

Latif, Hira ^{[1
]}

Liu, Stephen V. ^{[2
]}

机构：

[1] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA

[2] Georgetown Univ, Dept Med, Washington, DC USA

来源：

ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷

关键词：

CELL LUNG-CANCER; CHECKPOINT INHIBITORS; ACTIVATION; MUTATIONS; GEFITINIB;

D O I：

10.21037/atm.2019.03.6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：3

共 17 条

[1] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[2] The polarization of immune cells in the tumour environment by TGFβ [J].

Flavell, Richard A. ;

Sanjabi, Shomyseh ;

Wrzesinski, Stephen H. ;

Licona-Limon, Paula .

NATURE REVIEWS IMMUNOLOGY, 2010, 10 (08) :554-567

[3] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[4] Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas [J].

Gao, Sizhi Paul ;

Mark, Kevin G. ;

Leslie, Kenneth ;

Pao, William ;

Motoi, Noriko ;

Gerald, William L. ;

Travis, William D. ;

Bornmann, William ;

Veach, Darren ;

Clarkson, Bayard ;

Bromberg, Jacqueline F. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3846-3856

[5] Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study [J].

Gettinger, Scott ;

Horn, Leora ;

Jackman, David ;

Spigel, David ;

Antonia, Scott ;

Hellmann, Matthew ;

Powderly, John ;

Heist, Rebecca ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Geese, William J. ;

Yoon, Dennis ;

Li, Ang ;

Brahmer, Julie .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1675-+

[6] Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC [J].

Gibbons, D. L. ;

Chow, L. Q. ;

Kim, D-W. ;

Kim, S-W. ;

Yeh, T. ;

Song, X. ;

Jiang, H. ;

Taylor, R. ;

Karakunnel, J. ;

Creelan, B. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S79-S79

[7] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[8] Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation [J].

Hui, E. P. ;

Ma, B. B. ;

Mo, F. ;

Kam, M. K. ;

Chan, S. L. ;

Loong, H. H. ;

Ho, R. ;

Leung, S. F. ;

King, A. D. ;

Wang, K. ;

Ahuja, A. ;

Chan, C. M. ;

Hui, C. W. ;

Wong, C. H. ;

Chan, A. T. C. .

ANNALS OF ONCOLOGY, 2016, 27

[9] Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis [J].

Lee, Chee Khoon ;

Man, Johnathan ;

Lord, Sally ;

Cooper, Wendy ;

Links, Matthew ;

Gebski, Val ;

Herbst, Roy S. ;

Gralla, Richard J. ;

Mok, Tony ;

Yang, James Chih-Hsin .

JAMA ONCOLOGY, 2018, 4 (02) :210-216

[10] Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis [J].